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Abstract
Background: Heparin has been shown to modify fundamental biologic processes ranging from
blood coagulation and cell proliferation to fibrogenesis and asthma. The goal of this study was to
identify specific or broad biologic responses of the rat lung to intratracheal instillation of heparin
by targeted proteomic analysis.
Methods: Rats were given either aerosolized 500 µg heparin in 250 µl saline or saline alone. Lungs
were harvested at 0, 24, or 96 hours post-treatment and isolated proteins analyzed by two-
dimensional gel electrophoresis. Proteins which increased and decreased significantly in treated
groups above controls were then selected for identification by mass spectrometry.
Results:  Although heparin treatments resulted in a general reduction in cytosolic protein
expression, there were significant increases within members of discrete groups of proteins. At 24
hours, proteins which function in cytoskeletal organization and in calcium signaling were up-
regulated between 2- and 27-fold above baseline and untreated controls. Increased proteins include
annexins V and VI, septin 2, capping G protein, actin-related protein 3, moesin, RhoGDP
dissociation inhibitor, and calcyclin. A group of proteins relating to immune response and tumor
suppressor function were either up-regulated (tumor suppressor p30/hyaluronic acid binding
protein-1, Parkinson disease protein 7, proteosome 28 subunit/interferon-γ inducible protein, and
proteosome subunit macropain α-1) or strongly down-regulated (transgelin). At 96 hours, most
proteins that had increased at 24 hours remained elevated but to a much lesser degree.
Conclusion: These cumulative observations demonstrate that whole lung heparin treatment
results in significant up-regulation of selected groups of proteins, primarily those related to
cytoskeletal reorganization and immune function, which may prove to be relevant biomarkers
useful in analysis of lung exposures/treatments as well as in system biology studies.
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Background
Proteomic studies performed on whole organs can pro-
vide a useful, broader perspective from which to view a
biological event [1,2]. As applied to the lung, this
approach may provide important information on func-
tional groups of proteins, a prerequisite for systems biol-
ogy studies, while supporting dynamic modeling.
Ultimately, pulmonary function or its disturbance can be
thought of as the result of the interactions of a dynamic
group of proteins originating from a diverse population of
cells varying in, activation states and levels of maturity,
which collectively constitute the lung proteome [3].
Heparin, a model heparan sulfate proteoglycan (HSPG),
has been previously shown to reduce or inhibit prolifera-
tion and gene and protein expression in isolated rat lung
type II alveolar cells [4-6]. Similarly, heparin and/or
heparan sulfate have been shown to reduce proliferation
in lung fibroblasts [7-9] and lung smooth muscle cells
[10,11]. The current proteomic study was undertaken to
expand investigation into the effects of heparin-like mol-
ecules on whole lung, in vivo. Normal lung contains large
amounts of HSPGs, many of which are heavily sulfated.
Syndecan, an HSPG spanning the cytoplasmic membrane,
has a sulfated ectodomain comprised of a portion of the
core protein and a variable number of glycosaminoglycan
(GAG) side chains that can be enzymatically shed, both
constitutively at low levels and at much higher levels dur-
ing inflammation and tissue remodeling [12]. Heparin's
anti-coagulant activity is well established, but more
recently it has been appreciated for its antiproliferative
effects, as noted above, which can prevent lung damage
due to hypoxia [11], bleomycin-induced fibrosis [13] and
cancer [14]. These effects have been shown to be a func-
tion of the sulfated nature of these molecules, as desul-
fated or otherwise modified forms are not as effective [4-
6,9,10]. Heparin has also been shown clinically to inhibit
specific asthmatic responses in humans and prevent bron-
choconstriction in exercise-induced asthma by mecha-
nisms not fully understood [15-17]. It has been used
experimentally as a model component of extracellular
matrix and cell surface shedding [4-6,16].
The goal of this study was to identify specific proteomic
responses of normal rat lungs exposed to aerosolized
heparin using 2-dimensional gel electrophoretic separa-
tion and mass spectrometry (MS). Proteins so defined
could then serve as potential biomarkers or indicators of
responses to changes in the lung macro- and/or microen-
vironments that might be expected to increase during cell
surface ectodomain shedding as in injury or disease, in the
context of a lung systems biology approach. Although it is
not intended to serve as a complete catalogue of the whole
rat lung proteome, the results could be a useful reference
to future proteomic studies on rat lung.
Methods
In-vivo heparin treatments
Two groups of specific-pathogen-free (SPF) rats were used
in this study. The first group, analyzed as preliminary data
for the subsequent study, consisted of Fischer rats (n = 9)
(Charles River, Wilmington, MA) in 3 groups of 3 animals
each: untreated controls, heparin-treated and sacrificed
after 24 hours, and heparin-treated and sacrificed after 96
hours.
The second group consisted of Fischer rats (n = 15)(Har-
lan, Indianapolis, IN) in 5 subgroups of 3 animals each:
untreated, saline/vehicle control 24 hours, heparin-
treated 24 hours, saline/vehicle control 96 hours, and
heparin-treated 96 hours. One untreated control (base-
line/reference) was sacrificed at 0, 24, and 96 hours. Vehi-
cle controls and heparin-treated animals were sacrificed at
24 and 96 hours.
Rats weighing between 250 and 285 grams were given
intraperitoneally a mixture of 30 mg Ketaset (Fort Dodge,
Fort Dodge, IA) and 6 mg X-ject (Burns Veterinary Supply,
Inc., Westbury, NY) to induce anesthesia 15 min prior to
intratracheal administration of a single aerosolized dose
(250 µl) of normal saline or of a 2 mg/ml solution of high
molecular weight heparin, 13,500–15,000 MW, (Calbio-
chem, San Diego, CA) using a MicroSprayer intratracheal
aerosolizer (Penn-Century, Philadelphia, PA) to optimize
the distribution of heparin throughout the lung. Accord-
ing to the manufacturer, this generates 25–30 µm sized
particles, which should be capable of reaching first order
(primary) bronchioles. At 24 hours or 96 hours post-treat-
ment, the experimental and control animals were eutha-
nized with an overdose of sodium pentobarbital. The
lungs were perfused with saline until white to remove
blood and minimize albumin interference in later proce-
dures, then surgically removed from the pulmonary cav-
ity. Pulmonary airways (visible bronchi) were separated
by blunt dissection from the parenchyma (small airways
and alveolar regions) and the latter flash frozen in liquid
nitrogen and stored at -80°C for later analysis. In some
cases, the apical lobe of the right lung was tied off and
insufflated with 2% paraformaldehyde in 0.1 M phos-
phate buffered saline for 1 hour. Sections were dehydrated
with graded alcohols and infiltrated with xylenes followed
by paraffin. Paraffin embedded tissue blocks were cut into
7 µm sections on a standard microtome and prepared for
routine histology or immunostaining. Rabbit anti-
annexin V (FL-319; sc-8300, Santa Cruz Biotech, Santa
Cruz, CA) was applied at 1:100 dilutions overnight and
the antigen-antibody complex visualized with a
VectaStain Elite Peroxidase kit (Vector Laboratories, Burl-
ingame, CA).Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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Protein sample preparation
Frozen lung parenchyma was pulverized using a special-
ized mortar and pestle (Fisher Scientific, Suwanee, GA)
under liquid nitrogen. Equal amounts (250 mg) of pow-
dered lung were suspended in a urea-containing buffer
containing 20 µg/ml RNase-A, 100 µg/ml DNase-1 inhib-
itor (Invitrogen, Carlsbad, CA), 1% ampholytes (pH 3–
10), and 50 µM dithiothreitol (BioRad, LaJolla, CA). Pro-
tein concentrations were measured by chemilumines-
cence using Protein EZ-Quant (Invitrogen), with 100 µg
total lung lysate loaded per gel. All samples were diluted
in 6.25 M urea and 2.3 M thiourea buffer to a concentra-
tion of 1 mg/ml and stored frozen at -80°C. First-dimen-
sional Readystrips, pH 5–8, 11 cm (BioRad) were used for
all samples based on preliminary data that suggested the
majority of dynamically regulated proteins focused
between pH 5 and pH 8. Samples were applied to strips
and equilibrated for 12 hours at 50 V on a Protean X IEF
focuser (BioRad). Samples were isoelectrically focused at
250 V for 15 minutes. Voltage was increased by two 500 V
ramp increases until achieving 1500 V, held at 1500 V for
2 hours, and then increased in rapid steps to 8000 V until
complete isoelectric focus was achieved at 55 kVH.
Second-dimension electrophoresis and staining
Bis-Acrylamide gels (12.5%) with stackers (4%) were
hand-cast in a 16 cm × 18 cm gel slab Multicasting System
(Hoefer Scientific, Cambridge, MA). Gels were allowed to
polymerize overnight with n-butanol overlays. First-
dimension electrofocused strips were alkylated in 0.25%
iodoacetamide (BioRad) for 20 minutes on an orbital
shaker, rinsed with 1× Tris-Glycine-SDS running buffer,
and then carefully laid onto second-dimension gels. A
layer of 0.5% agarose containing bromophenol blue was
poured to keep strips in place. Multiple gels were run
simultaneously (to minimize group run variation) at 200
V for 6 hours, rinsed for 1 minute in 250 ml of ultra-pure
water twice, and fixed overnight in 10% methanol, 5%
glacial acetic acid on a horizontal shaker. Gels were incu-
bated in Sypro-Ruby stain (Molecular Probes, Carlsbad,
CA) in the dark for 16 hours.
Image capture and analysis
Gel images were captured with an Epi Chemi UVP scanner
supported by a 16 bit CCD camera for enhanced high res-
olution images (BioImaging Systems, Upland, CA). Aper-
ture width and exposure time were adjusted so that only
the most abundant spots on the gels reached saturation
(pixel intensity was determined by the software). In addi-
tion, gels were normalized based on total protein fluores-
cence per gel as well as reference spot fluorescence
comparison. The same settings were used for all gels.
Acquired gel images were analyzed using PDQuest soft-
ware (BioRad), transformed to adsorption images (dark
spots against light background), cropped, and size-
adjusted across all images. The effects of occasional streak-
ing were minimized by during the analysis with the appli-
cation of Guassian equations to the raw images with the
PDQuest software. Spot detection parameters were opti-
mized on a single gel representative of each individual
sample, then normalized among the sub-group, and
finally normalized across groups. Areas of interest were
assigned to the program for further magnification. Images
in each set were matched and a representative map was
generated for each individual and subsequently for each
sub-group per time point. Correlation coefficients of vari-
ance were calculated for each spot within sub-groups and
compared with the mean correlation coefficient of vari-
ance in the software program, which then assigned signif-
icance values to each spot. Only spots with optical
densities that were significantly changed by heparin
(based on the Mann-Whitney statistical technique) were
further analyzed for the purposes of this study.
Spot selection, digestion, and protein analysis
After selection of the most dynamically-regulated spots,
gel plugs were manually excised from replicate gels (n =
3), placed in a 96-well plate, trypsin-digested overnight
on an automated digester, and placed on zip-plates (Mill-
ipore Bioscience, Bedford, MA) to remove any salts that
could adversely affect results. Bovine albumin was added
to the Maldi plate as a positive control for MS detection.
Replicate samples and control proteins were resuspended
in 5 µl of 30% acetonitrile/0.1% trifluoroacetic acid. One
µl of each sample was spotted twice, allowing the spot to
air dry completely each time. Matrix (alpha-cyano-4-
hydroxycinnamic acid, Agilent Technologies, Palo Alto,
CA) (0.5 µl) was overlaid on each spot. An ABI-4700 Pro-
teomics Analyzer MALDI-time of flight/time of flight
(TOF/TOF) mass spectrometer (Applied Biosystems, Fos-
ter City, CA) was used for the analysis. The instrument was
set to acquire an initial MS spectrum followed by up to 15
MS/MS spectra for each spot. The instrument was inter-
nally calibrated using a mixture of 6 peptides. A default
"plate" calibration was performed based upon 6 calibra-
tion spots distributed on the plate, resulting in accuracies
better than 100 ppm. For the analysis of sample spots, the
instrument attempted to perform an internal calibration
for the individual spots using the tryptic autodigest frag-
ments, which resulted in accuracies better than 20 ppm. If
the instrument was unable to perform the internal calibra-
tion, the default "plate" calibration was applied to the
sample spot. The MS and MS/MS data were processed by
GPS Explorer, version 2.0 (Applied Biosystems), and sub-
mitted to our in-house MASCOT search engine (Matrix
Science). The NCBI non-redundant database was searched
with tolerances set to 150 ppm for the MS spectra and 0.5
kDa for the MS/MS spectra. GPS Explorer then processed
the search results from MASCOT.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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Results
Lung histology
Tissues prepared for morphologic examination indicated
no gross or microscopic alterations in lung architecture
due to the instillation of heparin at any of the time points
examined (Figs. 1A–D).
Preliminary experiment analysis
Initially, 4128 spots were detected within the preliminary
data set using PDQuest software and liberal parameters.
Parameters of very high stringency in combination with a
most conservative threshold then allowed the software to
reassign 1682 spots for comparison. The software identi-
fied 551 differentially-expressed (increased/decreased)
proteins, not all of which were obvious to the unaided
eye. Of those, 54 protein spots were selected as the highest
priority candidates based on the magnitude of change in
expression and were further analyzed by mass spectrome-
try.
Particularly large or diffuse spots, such as those likely con-
taining multiple proteins or representing albumin and/or
transferrin, were not considered good candidates for
quantitative analysis by MS and were excluded from fur-
ther analysis.
Controlled experiment analysis
Across the controlled experiment data set, 3103 spots
were detected using the software at liberal parameters.
With more stringent parameters, the software reassigned
942 spots for further comparison. Technical stringency
indicated almost identical protein migration patterns
(Figs. 2A–D) between experiments (especially Heparin
treatments), hence achieving a higher degree of analytical
confidence. Next, the software was able to identify 377
differentially-expressed proteins within the spots, which
were again examined in a hierarchical manner.
Analysis of combined experiments
There were no visual or analytical differences between
untreated, saline 24 hours, and saline 96 hours sub-group
samples (CV% range of 0.01–0.1). Comparisons by the
imaging software of images from replicate samples within
experimental subgroups (CV% of 0.05) and between
maps of untreated controls and vehicle control groups
indicated no statistically-significant differences (within
95% confidence levels). The repeatability of patterns
between sub-groups enabled reliable statistical analysis of
changes in protein expression/spot detection, as demon-
strated in Figure 2A–D. Images with equivalent statistical
strengths across replicates within subgroups were aligned
to generate reference templates per subgroup which were
stacked a second time across trials to generate per group
templates/reference maps. Combining these images gen-
erated a single template per group with a higher confi-
dence interval. (i.e. if a spot is in the template, it is found
in all members of that subgroup). This resulted in a given
protein spot being more heavily weighted statistically and
Light micrographs depicting representative, random histologic fields from the various treatment groups indicated (A-D) Figure 1
Light micrographs depicting representative, random histologic fields from the various treatment groups indicated (A-D). No 
significant changes in lung architecture, cell infiltrates, or cell numbers were apparent with any of the treatments and the 
respective time points. Magnification ×250. Bar = 40 µM.
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Protein maps representative of each of the treatment sub-groups analyzed in side by side comparison and filtered baseline ref- erence map annotation Figure 2
Protein maps representative of each of the treatment sub-groups analyzed in side by side comparison and filtered baseline ref-
erence map annotation. A. Control treatment, B. heparin 24 hours, C. heparin 96 hours, and D. a computer analyzed, 2D 
Gaussian filtered lung reference map with the identified protein spots, separated based on pI and molecular weight (Mr). Note 
repeatability between sub-groups.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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a lower coefficient of variance per candidate spot, and per-
mitted the combination of the results of similar sub-
groups for generating reference/group templates. Com-
bining these data sets increased the power of subsequent
statistical analyses and aided in the choice of candidate
proteins for identification.
Heparin effects on selected proteins from cellular 
compartments
The selected protein peptides analyzed by Mass Spectrom-
etry were classified based on the predicted cellular com-
partmentalization of the native protein (Fig. 3). It is
interesting to note that the percentage of cytoskeleton-
related proteins almost doubled among those proteins
increased by heparin (Figs. 3A–C). It is understood that
some of the larger spots may have masked or otherwise
obscured some regulated proteins. However, due to MS
limitations of the technique applied in this study
(MALDI-TOF/TOF-MS), these proteins spots were not
good candidates for quantitative analysis. But it was the
purpose of the study to examine those discrete and iden-
tifiable proteins whose change in expression exceeded an
established threshold (see Methods).
Overall protein expression changes at 24 hours
A total of 25 candidate proteins were identified as
increased at 24 hours post-heparin treatment and an
equal number of candidate proteins were selected due to
their significant down-regulation pattern or unchanged
status, based on comparisons with the control group gels
(Fig. 2). Image analysis confirmed these trends on the
pixel level. Protein quantity change was considered signif-
icant if expression change was greater than 1.7-fold (p <
0.5) (Tables 1 and 2) and CV% were less than 0.1. One of
the advantages of separating proteins on 2D gels is the
ability to cross-examine MS identifications with protein
mobility characteristics. Therefore, the combined results
from the image analysis and the MS identification were
confirmed by the agreement of mass and iso-electric
focusing values calculated via Swiss PDB for the 21 iden-
tified proteins satisfying the significance criteria (Tables 1
and 2).
MS identification according to cellular compartment protein expression Figure 3
MS identification according to cellular compartment protein expression. A. Percentage of the proteins identified by MS in con-
trol lungs with respect to cell compartment. B. Cell compartment distribution of identified increased proteins in heparin-
treated lungs. C. Distribution of identified reduced proteins in heparin-treated lungs.
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Table 1: Increased protein expression profiles
Protein Identified Accession # Mr/D pl Magnitutde of expression change 0.96 hr CV% Protein score
0.24 hr 0.24 hr CV% 24.96 24.96 hr CV% 0.96
Parkinson disease prot.7/Drosophila prot. J-1 PARK-7/DJ-1 gi|16924002 19961.4 6.32 30.05* 0.03 0.34 0.03 10.19* 0.03 108
Annexin V gi|1421099 10028.3 5.3 27.00* 0.12 0.48 0.03 13.02* 0.02 312
Rat tumor suppressor p30/Hyaluronic acid binding protein 1 homologue HABP-1 gi|34097946 61034.1 6.2 15.02* 0.05 0.73 0.05 11.00* 0.05 77
Heat shock protein k71 mutant w ATpase gi|1943516 41866.6 6.36 6.44* 0.03 0.5 0.02 3.24* 0.03 92
Annexin VI gi|13994159 75706.5 6.39 6.22* 0.02 0.5 0.02 3.10* 0.01 313
Septin 2 gi|16924010 41566.3 6.15 4.19* 0.02 0.24 0.02 1.00 0.02 118
Capping G protein gi|18605629 38744.7 6.47 4.18* 0.02 0.24 0.03 1.00 0.02 375
Actin related protein 3 Actr-3 gi|34879484 55252.4 6.55 4.14* 0.02 0.5 0.02 2.07* 0.01 310
Proteosome 28 subunit(PA28)/Interferon gamma inducible protein (IGIP) gi|8394088 28559.1 5.77 3.98* 0.01 0.62 0.03 2.48* 0.02 228
Moesin gi|13540689 6769.8 6.16 3.12* 0.01 0.46 0.01 144 0.01 496
Rho GDP dissociation inhibitor (Rho-GDI) gi|56541074 23392.8 6.12 2.93* 0.02 0.47 0.01 1.38 0.02 77
Calcyclin/S100A6 gi|13506725 10028.3 5.3 2.71* 0.03 0.03 0.08 0.09* 0.01 121
Carboxylesterase 3 gi|31542380 62107.7 6.1 2.24* 0.05 0.2 0.3 0.45* 0.03 205
Phosphatidyl Inositol transfer protein (PITPN) gi|6679337 31873 5.97 2.03* 0.02 0.44 0.01 0.90 0.02 93
Heat shock protein 70_90 chaperone gi|20302113 62530.4 6.4 2.00* 0.02 0.23 0.02 0.46* 0.02 271
Proteosome Subunit macropain alpha (PSMA-1) gi|38328483 29498.8 6.15 1.99* 0.2 0.51 0.01 0.99 0.02 223
* significant change compared with untreated controls (p < 0.05; or greater than 1.7 fold increase)
Protein score – A "score" based on the frequency of a fragment molecular weight found in a protein of a given range of molecular weight. For every database entry scanned, all matching fragments 
contribute to the final score.
Protein C.I.% – Confidence interval that the program assigns to the peptide matches to protein. >95% score was considered statistically significant.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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Specific groups of proteins changed by heparin at 24 hours
Proteins increased at 24 hours post-heparin treatment fell
into four major categories: 1) calcium signaling pathways,
2) cytoskeletal domains, 3) immune responses, and 4)
tumor suppression.
A cluster of proteins related to calcium signaling pathways
was found to be up-regulated following heparin treat-
ment. Proteomic analysis identified five proteins as up-
regulated: annexin V (ANXV) by >27-fold, annexin VI
(ANXVI) by > 7 fold, actin related protein 3 (Arp3) by >4-
fold, moesin (Msn) by >3 fold, and calcyclin (Cacy/
S100A6) by >2.5-fold (Fig. 4A and Table 1).
Of the cytoskeleton domain proteins, Rho-GDP dissocia-
tion inhibitor (Rho-GDI) protein, a key regulator of the
Rho-GTPase family was increased by >3-fold; septin and
capping G (CapG), two proteins known to be involved in
actin filament polymerization, were increased by >5 fold
at 24 hours (Fig. 4B and Table 1). In addition, 2-phos-
phatidyl inositol phosphate transfer protein (PIPTN), a
member of the phosphatidyl-inositol-phosphate(PIP)/
inositol-phosphatidyl-3 (IP3) family, was increased by
>2-fold and Hsp70 doubled (Fig. 4B and Table 1). The
change in protein expression as a function of optical den-
sity of the electrophoretically resolved spot is further dem-
onstrated by Rho-GDI in an enhanced image (Figs. 5). The
increase in spot density from control/saline treatment
(Fig. 5A) to heparin treatment at 24 hours (Fig. 5B) and 96
hours (Fig. 5C) is visually evident.
Changes in the expression of two proteins related to
immune function were also reflected in the 24 hour post-
treatment proteome maps. Interestingly, interferon
gamma-inducible proteosome regulator IGIP/PA28, an
important modulator of immunoproteosome formation
and function, was increased nearly 4-fold (Fig. 4C and
Table 1). Proteosome subunit macropain alpha (PSMA-
1), known to bind and activate proteosomes critical to
immune response in the cytosol and nucleus of cells, was
increased nearly 2-fold (Fig. 4C and Table 1).
Drosophila protein J-1/Parkinson protein 7 (DJ-1/
PARK7), a negative regulator of PTEN tumor suppressor
and a potential prognostic marker for cancer, was
increased by >30-fold at 24 hours and the tumor suppres-
sor-related protein, hyaluronate binding protein-1
(HABP-1), was increased >15 fold (Fig. 4D and Table 1)
while transgelin (TAGLN2), was the most significantly
down-regulated protein at >14-fold (Fig. 4D and Table 2).
The change in DJ-1/PARK7 expression is further demon-
strated by in-gel enhancement through computer analysis
from control/saline treatment (Fig. 6A) compared to
heparin treatment at 24 hours (Fig. 6B) and 96 hours (Fig.
6C).
Immunostaining for annexin V
In order to gain some insight into the cellular localization
of upregulated proteins, annexin V was chosen as a repre-
sentative example. Figure 7 shows the immunoreactivity
for annexin V in fibroblasts, airway epithelium, macro-
phages, and alveolar type II cells in the normal rat lung
(Fig. 7A). Heparin treatment enhanced immunostaining
somewhat (Fig. 7B), with the understanding that immu-
noreactivity is difficult to truly quantify. Normal serum
controls developed no reactive contrast (Fig. 7C).
Overall protein expression changes at 96 hours
Lungs at 96 hours post-heparin clearly showed a decrease
of many proteins compared to the 24 hours post-heparin
group. As with the 24 hour analysis, protein identifica-
tions were further confirmed by their agreement with the
separation patterns and the Mr calculations performed
using the Swiss PDB tool (Tables 1 and 2). There was min-
Table 2: Reduced protein expression profiles
Protein Identified Accession # Mr/D pl Magnitude of expression change 0.96 hr 
CV%
Protein 
score
protein 
C.I.%
0.24 hr 0.24 hr 
CV%
24.96 24.96 hr 
CV%
0.96
Transgelin 2 homologue (Sm22 alpha) gi|34880944 29950.9 8.72 14.00* 0.02 1.00 0.11 14.0* 0.07 114 100.00
Pyruvate dehydrogenase lipoamide beta gi|50925725 38957 6.2 7.50* 0.02 0.75 0.05 5.63* 0.01 119 100.00
CAPPA1 homologue gi|34859736 32889.3 5.43 3.47* 0.05 4.05 0.05 14.4* 0.03 375 100.00
Lactate dehydrogenase b gi|6981146 36589.1 5.7 3.08* 0.02 1.46 0.01 4.51* 0.02 583 100.00
Dimethylarginine Dimethylaminohydrolase 
2 (DDAH-2)
gi|46237608 29669.4 5.66 2.75* 0.03 0.86 0.04 2.36* 0.07 203 100.00
* significant change compared with untreated controls (p < 0.05; or greater than 1.7 fold increase)
Protein score – A "score" based on the frequency of a fragment molecular weight found in a protein of a given range of molecular weight. For 
every database entry scanned, all matching fragments contribute to the final score.
Protein C.I.% – Confidence interval that the program assigns to the peptide matches to protein. >95% score was considered statistically 
significant.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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imal statistical difference between the treatment sub-
groups in expression of the selected proteins, with most
being reduced from the 24 hour period. However, most
remained elevated above control levels. Those remaining
significantly increased at the 96 hour post-heparin time
point were ANXV, ANXVI, Arp3 (Fig. 4A and Table 1),
IGIP/p28 (Fig. 4C and Table 1), and HABP-1, and DJ-1/
PARK7 (Fig. 4D and Table 1).
Discussion
This report describes the 2D gel electrophoresis and MS
analysis of selected proteins in normal and heparin-
treated rat lung and identifies proteins that change in
quantity 24 and 96 hours after a single in-vivo aerosol
exposure to heparin. The twenty most dynamically
expressed proteins were selected at the time points tested
in the study and further analyzed by MS. They represent
potential biomarkers or indicators of cellular/tissue
responses to heparin and sort into specific categories that
could be useful in a systems biology approach to create a
mechanistic model of heparin's actions on whole rat lung.
Calcium signaling pathways
Based on lung proteome analysis, ANXV, which is a cal-
cium- and phospholipid-binding protein, had the second
greatest increase (>27-fold change at 24 hours) and the
Graphs of protein spot densities represent the time course of heparin's effects on levels of proteins with the greatest change in  expression, as detected in 2D gels and identified by MS, due to heparin instillation in rat lung Figure 4
Graphs of protein spot densities represent the time course of heparin's effects on levels of proteins with the greatest change in 
expression, as detected in 2D gels and identified by MS, due to heparin instillation in rat lung. A. Calcium signaling pathway 
proteins indicated increases in ANXV, ANXVI, calcyclin, ARP3, and moesin (Msn) at 24 hours. While by 96 hours all were 
reduced from 24 hour levels, only calcyclin was reduced to below 0 hour control levels. B. Cytoskeletal domain proteins 
RhoGDI, septin, CapG, PIPTN, and HSP70 were increased at 24 hours. All decreased to control levels (0 hours) or less by 96 
hours. C. Two immune response-related proteins, IGIP/PA28 and PSMA-1, were increased at 24 hours, and decreased by 96 
hours. D. Two proteins relating to tumor suppression, DJ-1/PARK-7 and HABP-1, were increased at 24 hours and reduced by 
96 hours, while Transgelin was reduced from control levels at 24 hours and remained low through 96 hours after heparin 
treatment. Note that Arp3 and Msn are found in the cytoskeletal domain as well as being grouped with the calcium signaling 
proteins but were graphed only once in A.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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greatest increase overall by 96 hours (>13-fold). Annexins
have previously been shown to bind to GAG's in the pres-
ence of calcium. Perhaps relatedly, calcyclin (S100A6),
another calcium-binding protein, was increased nearly 3-
fold at 24 hours post-heparin. Calcyclin is known to bind
to ANXV in the presence of calcium [18]. The calcyc-
lin+Ca+ANXV complex has been shown to be involved in
actin polymerization via the Arp2/3 complex [18-20];
Arp3 was one of the identified proteins increased in this
proteomic analysis. Actin polymerization could subse-
quently enhance the dynamic relocation of cytoskeleton-
linking attachment proteins [19] such as moesin, also
observed to be increased in this study. These cumulative
observations support the notion that heparin treatment of
whole lung as in the present study and as has been previ-
ously reported in cell cultures [19,21] results in calcium
influx into lung cell cytosolic compartments and triggers
significant increases in expression or relocation of selected
groups of proteins related to cytoskeletal reorganization
and immune function.
Cytoskeletal domains
It has been demonstrated that inhaled heparin can pre-
vent exercise-induced bronchoconstriction in asthma
patients [15,17], and there is evidence suggesting
heparin's potential in promoting wound healing [22-24]
and in preventing lung fibrosis [13,25,26], although the
underlying mechanisms involved remain unclear. In this
study it was found that a number of cytoskeleton-related
proteins were increased at 24 hours post-heparin treat-
ment. Based on bioinformatics and biological data-min-
ing models, these results support the notion that heparin
treatment appears to increase selected contractile and
structural elements in the lung. Specifically, Rho-GDI pro-
tein was found to be increased >3-fold at 24 hours post-
heparin. Rho-GDI is known to bind the key activator, Ras,
Illustrated is the expression of Rho-GDI protein stained with Sypro-Ruby across all master group-reference maps Figure 5
Illustrated is the expression of Rho-GDI protein stained with Sypro-Ruby across all master group-reference maps. A. Control, 
B. 24 hrs, and C. 96 hrs post-treatment. The expression of Rho-GDI increased 3+ fold from A to B.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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which actuates important cellular events including cellu-
lar growth, movement, apoptosis, and immune regula-
tion. The binding is known to be inhibitory of Rac, a small
GTPase involved in cytoskeleton contractility [27]. Both
events might be expected to reduce/prevent contractile
events, such as bronchoconstriction. This same inhibition
may promote cellular adhesion events and cytoskeletal
stability. Perhaps relatedly, other contractile/cytoskeletal
proteins were also found to be increased by heparin.
Moesin and PIPTN were up-regulated >3-fold and >2-
fold, respectively, by 24 hours. Moesin and PIPTN enable
the cytosolic RhoA/Rho-GDI complex to partially unfold
and reveal hydrophobic regions which are able to attach
to cell membrane surfaces, and in doing so, release Rho-
GTP proteins – active in cytoskeletal reorganization [28-
33]. Moesin, a significant attachment protein, binds to the
cell surface HSPG, syndecan-2 [34]. In addition to being
implicated in cell migration and actin cytoskeletal reor-
ganization, PIPTN – also identified as increased >2-fold
by heparin – has been shown to independently activate
NADPH protein [35]. Receptor stimulation transmitted
by Rho and PIPTN activates proteins at the leading edge of
migrating cells and recruits other actin-related proteins,
such as Arp3 (also increased >4-fold by heparin) in com-
plex with Arp2, and actin monomers, to induce actin fila-
ment branching and membrane protrusion. This can be
accomplished through activation of scaffold proteins
called WASp's, which are capable of activating the Arp2/3
complex and promoting actin cytoskeleton polymeriza-
tion [36]. Polymerization has been shown to accelerate
when WASp is in the presence of septin, another protein
increased by heparin treatment in the present study (Fig.
3B). It has also been suggested that there are direct rela-
tionships among septin, the actin cytoskeleton, and the
Rho family of proteins [37]. Another protein increased by
heparin was heat shock protein 70, HSP70 (~2-fold),
Pseudocolor density image, of in-gel image comparison of expression change for DJ-1/PARK-7 protein across all group maps Figure 6
Pseudocolor density image, of in-gel image comparison of expression change for DJ-1/PARK-7 protein across all group maps. 
A. Control, B. 24 hrs, C. 96 hrs.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
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which mediates cytoprotective effects through its function
as a molecular chaperone and through the phosphoryla-
tion-dependent stabilization of actin filaments [38].
It's worth noting that the cell type(s) and their numbers
with increased expression of cytoskeletal proteins is not
known from these studies. Smooth muscle cells and the
transition of interstitial fibroblasts to myofibroblasts
might be logical sources of the observed increases. Early
work suggested that heparin induces smooth muscle actin
expression and differentiation of myofibroblasts [39].
More recent studies suggest that heparin in combination
with fibroblast growth factors prevent myofibroblast dif-
ferentiation [40,41] – perhaps more likely a scenario to be
expected in an in vivo environment. Expansion of smooth
muscle is an even less likely source, since heparin is well
recognized for its antiproliferative effects on these cells.
Future studies will hopefully clarify this important point
and area of investigation.
Immune response
There is increasing evidence for the anti-inflammatory
effects of heparin [5,6,12,42-45]. The current study sup-
ports this body of evidence by reporting heparin's effects
Light micrographs depict representative histologic fields from the various treatment groups indicated (A-C) Figure 7
Light micrographs depict representative histologic fields from the various treatment groups indicated (A-C). A. Annexin V 
immunostaining is seen in bronchiolar (Br) lining epithelium and associated fibroblast layer (double arrows) and alveolar type II 
epithelial cells (single arrows). Annexin V is also demonstrated in endothelium in pulmonary vessel (V). Magnification ×300. Bar 
= 30 µm. B. Annexin V immunostaining from a heparin-treated lung shows similar features to A, but with generally an increase 
in overall staining, including macrophages (m), not depicted in panel A. Magnification ×300. Bar = 30 µm. C. Histochemical con-
trol treated with normal rabbit serum (NRS) in place of rabbit anti-annexin V. Magnification ×200. Bar = 50 µm.Respiratory Research 2007, 8:36 http://respiratory-research.com/content/8/1/36
Page 13 of 15
(page number not for citation purposes)
on the expression of two proteins important in the
immune response. IGIP/PA28 plays key roles in immune
response mechanisms [46,47] and has been shown to act
in intracellular immune functions via cytoskeletal mem-
brane trafficking and processing, possibly through its
binding to Hook3 protein, an actin-microtubule-binding
protein [48]. In concert with the combination of several
regulatory events, IGIP/PA28 aids in production of MHC
class 1 antigen in interferon gamma-stimulated cells
[49,50]. Interestingly, heparin and/or IGIP/PA28 also
stimulate STAT-1 and STAT-3 pathways, which are anti-
inflammatory in a number of cell models [51,52]. The sec-
ond protein, PSMA-1, along with IGIP/PA28, activates
proteosomes which produce antigenic peptides required
for the stimulation of immune responses [50].
Tumor suppression
DJ-1/PARK7, a negative regulator of the tumor suppressor
PTEN and promoter of proliferative pathways and cell sur-
vival [53,54], was increased (>30-fold) at 24 hours. It's
not clear how this reconciles with heparin's established
anti-proliferative effects on cells in general, but may
reflect a more specific response that remains to be illuci-
dated. Heparin's known anti-tumor effects may be
reflected in our observation that, at 24 hours post-heparin
treatment, the tumor suppressor protein HABP-1 is
increased >15-fold. In addition, transgelin, an actin bind-
ing cytoskeletal protein known also to have a role in cal-
cium interactions of smooth muscle cells, was the most
significantly reduced protein at 14-fold. Transgelin is
associated with cellular changes in idiopathic pulmonary
fibrosis (IPF) and was previously proposed to be a candi-
date tumor antigen [55-58]. The mechanisms for these
changes present intriguing targets for future studies.
Overall protein expression changes at 96 hours
It is important to note that nearly half of the proteins
detected which related to cytoskeletal reorganization
return to nearly baseline/control levels of expression by
96 hours. There was a general decrease in protein expres-
sion by 96 hours post-treatment compared to the 24
hours time-point. It is likely that the effects of heparin on
most cells decrease with time, since the animals were not
retreated. This is consistent with other in vivo and in vitro
studies from our lab. Other proteins, like ANXV, ANXVI,
IGIP/PA28, and HABP-1, were increased at 24 hours and
remained highly elevated at 96 hours – and indication
that heparin has more extended effects on selected pro-
teins.
Conclusion
In the present study, alterations of the rat lung proteome
in response to heparin are detailed for the first time. The
majority of proteins that were up-regulated were related to
calcium signaling and cytoskeletal organization, as evi-
denced by the strong increases in ANXV and ANXVI, Msn,
RhoGDI, PIPTN, calcyclin, and Arp3. These may serve as
potential biomarkers or indicators of baseline response to
changes in the lung macro- and/or microenvironments,
aiding in further understanding of the lung proteome, in
addition to understanding specific organ responses to
challenge or stimulation. This, and the indication that
other major groups of proteins related to immune func-
tion and control of cell growth were also responsive to
heparin treatment, suggests that heparin's known sup-
pressive effects upon lung fibrosis and even some cancers
may result from its effects upon cell shape and motility,
moderation of cell growth, and stimulation of the
immune response. This approach may prove useful to
future systems biology studies addressing changes to tis-
sue architecture of lung, such as asthma, chronic obstruc-
tive lung disease, and cystic fibrosis. Further, these results
also raise the possibility that shed surface ectodomains of
proteoglycans, as modeled in this study by heparin, may
have a broader influence on biological responses in the
lung than previously appreciated. Future studies will help
clarify this potentially important issue.
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